First Trust Advisors
PLRX icon

First Trust Advisors’s Pliant Therapeutics PLRX Stock Holding History

First Trust Advisors’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-70,709
Closed -$1.28M – 2464
2023
Q2 		$1.28M Buy
+70,709
New +$1.67M ﹤0.01% 1903

Other funds holding PLRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

First Trust Advisors's PLRX Position: Q3 2023 in Review

First Trust Advisors sold out of Pliant Therapeutics (PLRX) in Q3 2023, closing a stake of 70,709 shares — an estimated $1.28M sold.

First Trust Advisors first reported a position in PLRX in Q2 2023 and held it in 1 quarter. The position peaked at $1.28M in Q2 2023. 136 funds tracked by Wall St. Rank hold PLRX as of Q3 2023.

  • First Trust Advisors reported no remaining Pliant Therapeutics position as of Q3 2023 after selling out during the quarter.
  • First Trust Advisors sold 70,709 Pliant Therapeutics shares in Q3 2023, an estimated $1.28M.
  • First Trust Advisors first reported a position in Pliant Therapeutics in Q2 2023 and held it in 1 quarter.
  • First Trust Advisors's Pliant Therapeutics position peaked at $1.28M in Q2 2023.
  • 136 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2023.

Based on First Trust Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.